The UKABCS Grant-Winning Team from Helwan University is currently working on an innovative computational research project focused on the identification and prioritisation of potential therapeutic candidates against brain cancer. The project, titled “Target-Based QSAR, Virtual Screening, and Molecular Docking for the Identification of Potential Therapeutic Candidates Against Brain Cancer,” applies an integrated computational drug discovery strategy to address one of the most challenging areas in modern cancer research. Brain cancer continues to represent a significant therapeutic challenge, highlighting the need for efficient approaches capable of identifying and prioritising promising molecular candidates at the early stages of drug discovery. In response to this challenge, the Helwan University team is developing a structured computational workflow that combines target-based quantitative structure–activity relationship (QSAR) modelling, virtual screening, and molecular docking. The research focuses on four human molecular targets with important relevance to brain cancer: Epidermal Growth Factor Receptor (EGFR) Isocitrate Dehydrogenase 1 (IDH1) Cyclin-Dependent Kinase 4 (CDK4) Poly [ADP-ribose] Polymerase 1 (PARP1) The study will begin with the curation and preparation of target-specific bioactivity datasets, followed by QSAR analysis to investigate the relationship between chemical structure and biological activity. This stage will support the identification and prioritisation of compounds with favourable predicted activity against the selected therapeutic targets. The prioritised candidates will then undergo virtual screening and molecular docking, enabling the research team to evaluate their predicted binding affinity and investigate their potential molecular interaction patterns with the selected protein targets. By integrating ligand-based activity prediction with structure-based molecular interaction analysis, the project aims to establish a systematic framework for comparing and prioritising potential therapeutic candidates across multiple brain cancer-related targets. The expected outcomes of the research include the identification of promising molecular candidates with favourable predicted activity and target-binding profiles, providing a computational foundation for their subsequent investigation and experimental validation. Beyond the identification of individual candidates, the project represents an important application of computational approaches to early-stage drug discovery, demonstrating how data-driven modelling and molecular simulation can be integrated to support the rational prioritisation of potential therapeutic compounds. The UKABCS team at Helwan University is currently progressing with the research, and further findings from the study will be shared upon completion of the relevant research stages. The full research work is expected to be published soon, God willing, following completion of the study and the appropriate scientific publication process. UKABCS is proud to support emerging researchers and student-led scientific initiatives that apply advanced computational approaches to important challenges in biomedical research. This project reflects the growing potential of interdisciplinary research at the intersection of computational chemistry, bioinformatics, molecular modelling, and cancer drug discovery.
T
The UKABCS Grant-Winning Team from Helwan University is currently working on an innovative computational research project focused on the identification and prioritisation of potential therapeutic candidates against brain cancer. The project, titled “Target-Based QSAR, Virtual Screening, and Molecular Docking for the Identification of Potential Therapeutic Candidates Against Brain Cancer,” applies an integrated computational drug discovery strategy to address one of the most challenging areas in modern cancer research. Brain cancer continues to represent a significant therapeutic challenge, highlighting the need for efficient approaches capable of identifying and prioritising promising molecular candidates at the early stages of drug discovery. In response to this challenge, the Helwan University team is developing a structured computational workflow that combines target-based quantitative structure–activity relationship (QSAR) modelling, virtual screening, and molecular docking. The research focuses on four human molecular targets with important relevance to brain cancer: Epidermal Growth Factor Receptor (EGFR) Isocitrate Dehydrogenase 1 (IDH1) Cyclin-Dependent Kinase 4 (CDK4) Poly [ADP-ribose] Polymerase 1 (PARP1) The study will begin with the curation and preparation of target-specific bioactivity datasets, followed by QSAR analysis to investigate the relationship between chemical structure and biological activity. This stage will support the identification and prioritisation of compounds with favourable predicted activity against the selected therapeutic targets. The prioritised candidates will then undergo virtual screening and molecular docking, enabling the research team to evaluate their predicted binding affinity and investigate their potential molecular interaction patterns with the selected protein targets. By integrating ligand-based activity prediction with structure-based molecular interaction analysis, the project aims to establish a systematic framework for comparing and prioritising potential therapeutic candidates across multiple brain cancer-related targets. The expected outcomes of the research include the identification of promising molecular candidates with favourable predicted activity and target-binding profiles, providing a computational foundation for their subsequent investigation and experimental validation. Beyond the identification of individual candidates, the project represents an important application of computational approaches to early-stage drug discovery, demonstrating how data-driven modelling and molecular simulation can be integrated to support the rational prioritisation of potential therapeutic compounds. The UKABCS team at Helwan University is currently progressing with the research, and further findings from the study will be shared upon completion of the relevant research stages. The full research work is expected to be published soon, God willing, following completion of the study and the appropriate scientific publication process. UKABCS is proud to support emerging researchers and student-led scientific initiatives that apply advanced computational approaches to important challenges in biomedical research. This project reflects the growing potential of interdisciplinary research at the intersection of computational chemistry, bioinformatics, molecular modelling, and cancer drug discovery.
T
The UKABCS Grant-Winning Team from Helwan University is currently working on an innovative computational research project focused on the identification and prioritisation of potential therapeutic candidates against brain cancer. The project, titled “Target-Based QSAR, Virtual Screening, and Molecular Docking for the Identification of Potential Therapeutic Candidates Against Brain Cancer,” applies an integrated computational drug discovery strategy to address one of the most challenging areas in modern cancer research. Brain cancer continues to represent a significant therapeutic challenge, highlighting the need for efficient approaches capable of identifying and prioritising promising molecular candidates at the early stages of drug discovery. In response to this challenge, the Helwan University team is developing a structured computational workflow that combines target-based quantitative structure–activity relationship (QSAR) modelling, virtual screening, and molecular docking. The research focuses on four human molecular targets with important relevance to brain cancer: Epidermal Growth Factor Receptor (EGFR) Isocitrate Dehydrogenase 1 (IDH1) Cyclin-Dependent Kinase 4 (CDK4) Poly [ADP-ribose] Polymerase 1 (PARP1) The study will begin with the curation and preparation of target-specific bioactivity datasets, followed by QSAR analysis to investigate the relationship between chemical structure and biological activity. This stage will support the identification and prioritisation of compounds with favourable predicted activity against the selected therapeutic targets. The prioritised candidates will then undergo virtual screening and molecular docking, enabling the research team to evaluate their predicted binding affinity and investigate their potential molecular interaction patterns with the selected protein targets. By integrating ligand-based activity prediction with structure-based molecular interaction analysis, the project aims to establish a systematic framework for comparing and prioritising potential therapeutic candidates across multiple brain cancer-related targets. The expected outcomes of the research include the identification of promising molecular candidates with favourable predicted activity and target-binding profiles, providing a computational foundation for their subsequent investigation and experimental validation. Beyond the identification of individual candidates, the project represents an important application of computational approaches to early-stage drug discovery, demonstrating how data-driven modelling and molecular simulation can be integrated to support the rational prioritisation of potential therapeutic compounds. The UKABCS team at Helwan University is currently progressing with the research, and further findings from the study will be shared upon completion of the relevant research stages. The full research work is expected to be published soon, God willing, following completion of the study and the appropriate scientific publication process. UKABCS is proud to support emerging researchers and student-led scientific initiatives that apply advanced computational approaches to important challenges in biomedical research. This project reflects the growing potential of interdisciplinary research at the intersection of computational chemistry, bioinformatics, molecular modelling, and cancer drug discovery.
T
The UKABCS Grant-Winning Team from Helwan University is currently working on an innovative computational research project focused on the identification and prioritisation of potential therapeutic candidates against brain cancer. The project, titled “Target-Based QSAR, Virtual Screening, and Molecular Docking for the Identification of Potential Therapeutic Candidates Against Brain Cancer,” applies an integrated computational drug discovery strategy to address one of the most challenging areas in modern cancer research. Brain cancer continues to represent a significant therapeutic challenge, highlighting the need for efficient approaches capable of identifying and prioritising promising molecular candidates at the early stages of drug discovery. In response to this challenge, the Helwan University team is developing a structured computational workflow that combines target-based quantitative structure–activity relationship (QSAR) modelling, virtual screening, and molecular docking. The research focuses on four human molecular targets with important relevance to brain cancer: Epidermal Growth Factor Receptor (EGFR) Isocitrate Dehydrogenase 1 (IDH1) Cyclin-Dependent Kinase 4 (CDK4) Poly [ADP-ribose] Polymerase 1 (PARP1) The study will begin with the curation and preparation of target-specific bioactivity datasets, followed by QSAR analysis to investigate the relationship between chemical structure and biological activity. This stage will support the identification and prioritisation of compounds with favourable predicted activity against the selected therapeutic targets. The prioritised candidates will then undergo virtual screening and molecular docking, enabling the research team to evaluate their predicted binding affinity and investigate their potential molecular interaction patterns with the selected protein targets. By integrating ligand-based activity prediction with structure-based molecular interaction analysis, the project aims to establish a systematic framework for comparing and prioritising potential therapeutic candidates across multiple brain cancer-related targets. The expected outcomes of the research include the identification of promising molecular candidates with favourable predicted activity and target-binding profiles, providing a computational foundation for their subsequent investigation and experimental validation. Beyond the identification of individual candidates, the project represents an important application of computational approaches to early-stage drug discovery, demonstrating how data-driven modelling and molecular simulation can be integrated to support the rational prioritisation of potential therapeutic compounds. The UKABCS team at Helwan University is currently progressing with the research, and further findings from the study will be shared upon completion of the relevant research stages. The full research work is expected to be published soon, God willing, following completion of the study and the appropriate scientific publication process. UKABCS is proud to support emerging researchers and student-led scientific initiatives that apply advanced computational approaches to important challenges in biomedical research. This project reflects the growing potential of interdisciplinary research at the intersection of computational chemistry, bioinformatics, molecular modelling, and cancer drug discovery.
T
The UKABCS Grant-Winning Team from Helwan University is currently working on an innovative computational research project focused on the identification and prioritisation of potential therapeutic candidates against brain cancer. The project, titled “Target-Based QSAR, Virtual Screening, and Molecular Docking for the Identification of Potential Therapeutic Candidates Against Brain Cancer,” applies an integrated computational drug discovery strategy to address one of the most challenging areas in modern cancer research. Brain cancer continues to represent a significant therapeutic challenge, highlighting the need for efficient approaches capable of identifying and prioritising promising molecular candidates at the early stages of drug discovery. In response to this challenge, the Helwan University team is developing a structured computational workflow that combines target-based quantitative structure–activity relationship (QSAR) modelling, virtual screening, and molecular docking. The research focuses on four human molecular targets with important relevance to brain cancer: Epidermal Growth Factor Receptor (EGFR) Isocitrate Dehydrogenase 1 (IDH1) Cyclin-Dependent Kinase 4 (CDK4) Poly [ADP-ribose] Polymerase 1 (PARP1) The study will begin with the curation and preparation of target-specific bioactivity datasets, followed by QSAR analysis to investigate the relationship between chemical structure and biological activity. This stage will support the identification and prioritisation of compounds with favourable predicted activity against the selected therapeutic targets. The prioritised candidates will then undergo virtual screening and molecular docking, enabling the research team to evaluate their predicted binding affinity and investigate their potential molecular interaction patterns with the selected protein targets. By integrating ligand-based activity prediction with structure-based molecular interaction analysis, the project aims to establish a systematic framework for comparing and prioritising potential therapeutic candidates across multiple brain cancer-related targets. The expected outcomes of the research include the identification of promising molecular candidates with favourable predicted activity and target-binding profiles, providing a computational foundation for their subsequent investigation and experimental validation. Beyond the identification of individual candidates, the project represents an important application of computational approaches to early-stage drug discovery, demonstrating how data-driven modelling and molecular simulation can be integrated to support the rational prioritisation of potential therapeutic compounds. The UKABCS team at Helwan University is currently progressing with the research, and further findings from the study will be shared upon completion of the relevant research stages. The full research work is expected to be published soon, God willing, following completion of the study and the appropriate scientific publication process. UKABCS is proud to support emerging researchers and student-led scientific initiatives that apply advanced computational approaches to important challenges in biomedical research. This project reflects the growing potential of interdisciplinary research at the intersection of computational chemistry, bioinformatics, molecular modelling, and cancer drug discovery.
T
The UKABCS Grant-Winning Team from Helwan University is currently working on an innovative computational research project focused on the identification and prioritisation of potential therapeutic candidates against brain cancer. The project, titled “Target-Based QSAR, Virtual Screening, and Molecular Docking for the Identification of Potential Therapeutic Candidates Against Brain Cancer,” applies an integrated computational drug discovery strategy to address one of the most challenging areas in modern cancer research. Brain cancer continues to represent a significant therapeutic challenge, highlighting the need for efficient approaches capable of identifying and prioritising promising molecular candidates at the early stages of drug discovery. In response to this challenge, the Helwan University team is developing a structured computational workflow that combines target-based quantitative structure–activity relationship (QSAR) modelling, virtual screening, and molecular docking. The research focuses on four human molecular targets with important relevance to brain cancer: Epidermal Growth Factor Receptor (EGFR) Isocitrate Dehydrogenase 1 (IDH1) Cyclin-Dependent Kinase 4 (CDK4) Poly [ADP-ribose] Polymerase 1 (PARP1) The study will begin with the curation and preparation of target-specific bioactivity datasets, followed by QSAR analysis to investigate the relationship between chemical structure and biological activity. This stage will support the identification and prioritisation of compounds with favourable predicted activity against the selected therapeutic targets. The prioritised candidates will then undergo virtual screening and molecular docking, enabling the research team to evaluate their predicted binding affinity and investigate their potential molecular interaction patterns with the selected protein targets. By integrating ligand-based activity prediction with structure-based molecular interaction analysis, the project aims to establish a systematic framework for comparing and prioritising potential therapeutic candidates across multiple brain cancer-related targets. The expected outcomes of the research include the identification of promising molecular candidates with favourable predicted activity and target-binding profiles, providing a computational foundation for their subsequent investigation and experimental validation. Beyond the identification of individual candidates, the project represents an important application of computational approaches to early-stage drug discovery, demonstrating how data-driven modelling and molecular simulation can be integrated to support the rational prioritisation of potential therapeutic compounds. The UKABCS team at Helwan University is currently progressing with the research, and further findings from the study will be shared upon completion of the relevant research stages. The full research work is expected to be published soon, God willing, following completion of the study and the appropriate scientific publication process. UKABCS is proud to support emerging researchers and student-led scientific initiatives that apply advanced computational approaches to important challenges in biomedical research. This project reflects the growing potential of interdisciplinary research at the intersection of computational chemistry, bioinformatics, molecular modelling, and cancer drug discovery.
T